openPR Logo
Press release

Growth Dynamics on Orphan Drugs Market 2019-2025| Key Players: Bayer AG, Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S & more

06-19-2019 07:27 AM CET | Health & Medicine

Press release from: Fortune Business Insights

Growth Dynamics on Orphan Drugs Market 2019-2025| Key Players:

As per Fortune Business Insights, the North America Orphan Drugs Market was worth US$ 67,136.0 Mn in 2017 and will continue to rise at a steady pace until 2025. This is mainly ascribable to the rising awareness among people regarding the use of novel drugs. In addition to this, North America is expected to offer attractive growth opportunities on the back of recent FDA approvals on the development of orphan drugs. Governments in North America are increasingly spending on the research and development (R&D) of orphan drugs and technologies.

Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/orphan-drugs-market-100088

Some of the Main Key Players Covered in the Report:

• Bayer AG
• Hoffmann-La Roche Ltd.
• Alexion Pharmaceuticals Inc.
• Novo Nordisk A/S
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca plc.
• Daiichi Sankyo Company Limited
• GlaxoSmithKline plc.
• Amgen Inc.

North America is expected to remain dominant in the Global Orphan Drugs Market between 2018 and 2025. This information was found by Fortune Business Insights in a report, titled “Orphan Drugs Market: Global Market Analysis, Insights and Forecast, 2018-2025”. According to the report, the global orphan drugs market was valued at US$ 125000 Mn in 2017 and is anticipated to reach US$ 294000 Mn by 2025. The report also stated that the market will exhibit a remarkable CAGR of 11.4% during the forecast period

This is further helping the orphan drugs market to grow impressively in this region. Asia Pacific, on the other hand, is anticipated to show a higher rate of growth on account of rising prevalence of rare diseases such as chronic lymphocytic leukemia. Also, the region is expected to offer lucrative growth opportunities as a result of the rapid expansion of healthcare infrastructure.

Rising Prevalence of Cancer and Related Diseases Fuels Demand for Orphan Drugs

The oncology segment is witnessing considerably high demand on account of the rising number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market. According to the National Center for Health Statistics, the U.S. is likely to witness around 1,762,450 new cancer cases in 2019.

Spurred by these numbers, the demand for orphan drugs is likely to increase in the coming years. Governments are investing heavily to build a strong framework for supporting drug development, thus offering a significant impetus to the orphan drugs market. Furthermore, the return on investment, with regards to orphan drugs, is expected to be higher than non-orphan drugs, which in turn is increasing the demand for orphan drug therapeutics worldwide.

“People across the world are becoming more aware about the rising prevalence of rare disorders and importance of orphan drugs,” stated a lead analyst at Fortune Business insights. “This, coupled with robust support from EU and FDA to drug development, drives the orphan drugs market,” he added. Several pharma companies are also putting continuous efforts to develop orphan drugs, thus improving creating scope for generating more revenue in the overall global market for orphan drugs.

Treatment and Medications Associated with Rare Diseases Are Expensive, Limiting Growth of Orphan Drugs Market

Although the orphan drugs market is growing at a good pace, there are some factors that may hinder its growth. High cost of orphan drugs, insufficient information on rare diseases, and lack of skilled healthcare professionals are factors restricting growth in the global orphan drugs market. In addition to this, rising competition from generic industries may pose a serious threat to the growth of the market.

Emergence of New Players to Drive the Orphan Drug Market and Increase Competition

The global orphan drugs market is anticipated to pave way for the entry of several new players in the coming years. This is mainly because of the rapid drug development and discovery over the years. Several leading companies are manufacturing orphan drugs to build a nimble and agile framework. Some of the savvy players present in the global orphan drugs market are Actelion Pharmaceuticals Ltd., Biogen, Eli Lilly and Company, Bayer AG, Amgen Inc., and Pfizer Inc. These leading players are likely to give tough competition to the small entrants. Therefore, these small scale companies may need support from governments and other authorities to sustain in the market.

Browse Complete Report Details:
https://www.fortunebusinessinsights.com/industry-reports/orphan-drugs-market-100088

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities

Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Growth Dynamics on Orphan Drugs Market 2019-2025| Key Players: Bayer AG, Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S & more here

News-ID: 1780278 • Views:

More Releases from Fortune Business Insights

Reverse Flame Steam Boiler Market 2023 Dynamics, Major Players, SWOT Analysis, a …
Overview of the Global Reverse Flame Steam Boiler Market 2030: The report discusses everything a marketer requires before investing in the global Reverse Flame Steam Boiler Market during the forecast period 2023-2030. Reverse Flame Steam Boiler Market Size, Share And Global Trend By Capacity (Up to 100kW, 100-1000 kW, Above 1000 kW), By End-Use (Food Industry, Chemical Industry, Refineries, Metal Industry, Power Plant), And Geography Forecast Till 2022-2029. It provides detailed
Syngas and Derivatives Market Research Analysis, Size, Share, Growth Highlights …
Overview of the Global Syngas and Derivatives Market 2030: The report discusses everything a marketer requires before investing in the global Syngas and Derivatives Market during the forecast period 2023-2030. Syngas and Derivatives Market Size, Share and Global Trend By Feedstock(Coal, Petroleum, Natural Gas, Biomass), By Technology(Partial Oxidation, Steam Reforming, Auto-Thermal Reforming, and others), By End User(Chemicals, Power Generation, Liquid Fuels, Gaseous Fuels), and Geography Forecast till 2022-2029. It provides detailed
Port equipment Market Will Experience An Upswing In Demand, Driven By Top Players | Liebherr (Switzerland), TTS Group (Norway), Kalmar (Finland) Konecranes (Finland) |
Port equipment Market Will Experience An Upswing In Demand, Driven By Top Player …
The Port equipment Market Research Report provides an in-depth analysis of the market landscape and identifies future growth opportunities and trends until 2030. By offering valuable insights, the report enables companies to make informed decisions on business strategies and identify potential areas for growth. With a comprehensive assessment of the market, it equips businesses with the necessary tools to stay ahead of the competition. With this Port equipment Market research report,
Modular Chillers Market to reach USD 6.13 billion by 2026, at a CARG of 6.2% | LG Electronics, Mitsubishi Electric Corporation , Haier Group, Midea Group
Modular Chillers Market to reach USD 6.13 billion by 2026, at a CARG of 6.2% | L …
The Modular Chillers Market Report 2023 by Fortune Business Insights provides a comprehensive overview of the market's latest trends, size, regulations, key players, and strategies. The report offers valuable insights into the market's sales and revenue, product type, applications, regions, and leading players. Modular Chillers Market report also covers key players and competitor analysis, providing a comprehensive understanding of the industry's commercial landscape. The report is useful for gaining insights

All 5 Releases


More Releases for Orphan

Potential Opportunities of Orphan Drugs Market
As per Fortune Business Insights, the North America Orphan Drugs Market was worth US$ 67,136.0 Mn in 2017 and will continue to rise at a steady pace until 2025. This is mainly ascribable to the rising awareness among people regarding the use of novel drugs. In addition to this, North America is expected to offer attractive growth opportunities on the back of recent FDA approvals on the development of orphan
Orphan Drug Pipeline & Regulatory Insight 2025
Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs The global orphan drug market opportunity is expected to surpass US$ 260 Billion by 2025 as per
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the